Overview
| Product name | Recombinant Human BMPR-1A/ALK-3/CD292 Protein |
|---|
| Catalog No. | RP00156 |
|---|
| Description | Active Recombinant Human BMPR-1A/ALK-3 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gln24-Arg152) of human BMPRIA/ALK-3/CD292 (Accession #NP_004320.2) fused with an Fc, 6×His tag at the C-terminus. |
|---|
| Bio-Activity | Measured by its binding ability in a functional ELISA. Immobilized Human ACVR2B at 1 μg/mL (100 μL/well) can bind Human BMPRIA with a linear range of 0.5-62.5 ng/mL.
|
|---|
| Purity | > 95% by SDS-PAGE. |
|---|
| Endotoxin | < 0.1 EU/μg of the protein by LAL method. |
|---|
| Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation. |
|---|
| Species | Human |
|---|
| Calculated MW | 40.98 kDa |
|---|
Background
The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding.
Product information
| Synonym | BMPR1A; 10q23del; ACVRLK3; ALK3; CD292; SKR5 |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | C-hFc&His |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
